Cited by 243Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on BehaviorOpioid Use Disorder Treatment

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Pharmacological approaches to methamphetamine dependence: a focused review

Open access

Karila, Laurent, Weinstein, Aviv, Aubin, Henri‐Jean, Benyamina, Amine, Reynaud, Michel, Batki, Steven L.·2010·British Journal of Clinical Pharmacology

DOI 10.1111/j.1365-2125.2010.03639.xPMC PMC2883750

Open this paper in CoChat — free account Open PDF

Abstract

Methamphetamine dependence is a serious worldwide public health problem with major medical, psychiatric, socioeconomic and legal consequences. Various neuronal mechanisms implicated in methamphetamine dependence have suggested several pharmacological approaches. A literature search from a range of electronic databases (PubMed, EMBASE, PsycInfo, the NIDA research monograph index and the reference list of clinicaltrials.gov) was conducted for the period from January 1985 to October 2009. There were no restrictions on the identification or inclusion of studies in terms of publication status, language and design type. A variety of medications have failed to show efficacy in clinical trials, including a dopamine partial agonist (aripiprazole), GABAergic agents (gabapentin) and serotonergic agents (SSRI, ondansetron, mirtazapine). Three double‐blind placebo‐controlled trials using modafinil, bupropion and naltrexone have shown positive results in reducing amphetamine or methamphetamine use. Two studies employing agonist replacement medications, one with d‐amphetamine and the other with methylphenidate, have also shown promise. Despite the lack of success in most studies to date, increasing efforts are being made to develop medications for the treatment of methamphetamine dependence and several promising agents are targets of further research.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2010.03639.x

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine
Thompson, P. M., Hayashi, K. M., Simon, S. L., Geaga, J. A., Hong, M., Sui, Y., Lee, J. Y., Toga, A. W., Ling, W. W., & London, E. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0713-04.2004 · Cited by 770
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 669
Drug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1539 · Cited by 638
Involvement of the endocannabinoid system in drug addiction
Maldonado, R. J., Valverde, O., & Berrendero, F. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.008 · Cited by 601
Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G., Jayne, M. C., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 535
Cognitive enhancing effects of modafinil in healthy volunteers
Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J. H., & Sahakian, B. J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1250-8 · Cited by 518
The need for speed: an update on methamphetamine addiction
Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 441
The prevalence of psychotic symptoms among methamphetamine users
McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. M. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01496.x · Cited by 393
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391

Show all 135 references

Research works printed but not linked: 4

Urschel HC, 2008, A controlled trial of flumazenil, gabapentin and hydroxyzine in treatment of methamphetamine dependence, Puerto Rico, 56
Batki SL, 1999, Fluoxetine in methamphetamine dependence. A controlled trial: a preliminary analysis, Acapulco, 235
Batki SL, 2002, Methamphetamine‐amlodipine interactions: preliminary analysis, Drug Alcohol Depend, 66, S12
Batki SL, 2001, Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis, Drug Alcohol Depend, 63, 12

Sorted by citations

Items 101–200 of 243

Comparison of some behavioral effects of d- and l-methamphetamine in adult male rats
Siemian, J. N., Xue, Z., Blough, B. E., & Li, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4623-8 · Cited by 14
“Methamphetamine abusers suffer a variety of medical, psychological, socioeconomic, and legal consequences (Karila et al. 2010), and thus effective treatments are needed.”
Background
Long-term effects of young-adult methamphetamine on dorsal raphe serotonin systems in mice: Role of brain-derived neurotrophic factor
Sepulveda, M., Manning, E. E., Gogos, A., Hale, M. W., & van den Buuse, M. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147428 · Cited by 14
Update on methamphetamine: an old problem that we have recently encountered
Evren, C., & Bozkurt, M. (2018) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn20183101001 · Cited by 14
“There are no approved medications for treating methamphetamine-use disorder, and pharmacotherapy is recommended as an adjunct to psychosocial interventions rather than being a primary component of treatment (56) .”
Background
Maternal Methamphetamine Exposure Influences Behavioral Sensitization and Nucleus Accumbens DNA Methylation in Subsequent Generation
Dong, N., Zhu, J., Wang, R., Wang, S., Chen, Y., Wang, C., Goh, E. L. K., & Chen, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.940798 · Cited by 13
“Unlike opioid abusers, which can be treated with methadone replacement, pregnant women with METH dependence have no medication options for METH withdrawal (Karila et al., 2010).”
Background
Effects of 7-day continuous d-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys
Schwienteck, K. L., & Banks, M. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.022 · Cited by 13
“Currently, there is no Food and Drug Administration (FDA)-approved pharmacotherapy for the treatment of methamphetamine addiction (Brensilver et al., 2013; Carson and Taylor, 2014; Karila et al., 2010).”
Background
Alternative reinforcer response cost impacts methamphetamine choice in humans
Bennett, J. A., Stoops, W. W., & Rush, C. R. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.09.025 · Cited by 13
“Karila et al., 2010; Rush et al., 2009, for reviews).”
Background
A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy
Osekowski, M., Trytell, A., Gerche, A. L., Prior, D., MacIsaac, A. I., & Paratz, E. D. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00523-y · Cited by 13
“Dopamine agonists such as bupropion and modafinil have shown promise in reducing amphetamine use; however, trials are small, and further research is needed [35].”
Background
Effects of Modafinil on Sleep Pattern during Methamphetamine Withdrawal: A Double-blind Randomized Controlled Trial
Moosavi, S. M., Yazdani-charati, J., & Amini, F. (2019) · addiction and health · doi:10.22122/ahj.v11i3.219 · Cited by 12
Neuroprotective Effects of Berberine Hydrochloride on Methamphetamine-induced Cognitive Dysfunction: Immunohistochemical and Behavioral Studies in Rats
Rezaeian, L., Khaksari, M., Rafaiee, R., & Moghaddam, H. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.1444.2 · Cited by 12
“No approved pharmacotherapy, as well as confirmed medication, is available to treat MA abuse (Karila et al., 2010).”
Background
Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study
Guterstam, J., Jayaram‐Lindström, N., Berrebi, J., Petrović, P., Ingvar, M., Fransson, P., & Franck, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.023 · Cited by 12
The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice
Kitanaka, J., Kitanaka, N., Hall, F. S., Uhl, G. R., Fukushima, Y., Sawai, T., Watabe, K., Kubo, H., Takahashi, H., Tanaka, K.-I., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.05.027 · Cited by 12
Treatment of methamphetamine abuse: An antibody-based immunotherapy approach
Chen, Y., Wu, K., Tsai, H.-M., & Chen, C. (2013) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2013.09.040 · Cited by 12
“There is no approvedmedication forMethabuse, and thebroadmechanism of Meth action makes it difficult to develop an effective small molecule for pharmacotherapeutic intervention [6,7].”
Background
Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking
Phillips, T. J., Mootz, J. R. K., & Reed, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.001 · Cited by 12
The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?
Høj, S. B., Minoyan, N., Artenie, A. A., Grebely, J., & Bruneau, J. (2018) · Canadian Liver Journal · doi:10.3138/canlivj.1.2.003 · Cited by 11
Function of complement factor H and imaging of small molecules by MALDI-MSI in a methamphetamine behavioral sensitization model
Xu, J., Zhang, Z., Liu, R., Sun, Y. X., Liu, H., Nie, Z., Zhao, X., & Pu, X. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.002 · Cited by 11
“At present, METH dependence is a serious worldwide public health problem with major medical, psychiatric, cognitive, socioeconomic and legal consequences [5].”
Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance
Rush, C. R., Stoops, W. W., Lile, J. A., Glaser, P. E. A., & Hays, L. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.024 · Cited by 11
“Despite intense research efforts, a widely effective pharmacotherapy has not yet been identified for methamphetamine dependence (for reviews, see Elkashef et al., 2008a; Karila et al., 2010; Rush et al., 2009b; Vocci and Appel, 2007).”
Background
Memory impairment induced by amphetamine derivatives in laboratory animals and in humans: a review
Camarasa, J., Rodrigo, T., Pubill, D., & Escubedo, E. (2011) · BioMolecular Concepts · doi:10.1515/bmc.2011.048 · Cited by 11
“Federal Bureau of Investigation for other illnesses might also be useful for treating methamphetamine addiction (2) .”
Background
Commentary on H einzerling et al. (2014): A growing methamphetamine dependence therapeutics graveyard
Carson, D. S., & Taylor, E. R. (2014) · Addiction · doi:10.1111/add.12709 · Cited by 11
Parkin regulates drug-taking behavior in rat model of methamphetamine use disorder
SHARMA, A. K., Harutyunyan, A., Schneider, B. L., & Moszczyńska, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01387-7 · Cited by 9
Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.
Thoi, F., Scherer, D., Kaye, D., Sanders, P., & Stokes, M. (2022) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2021.12.015 · Cited by 10
The Effects of Oxytocin on Craving, Mental Health Parameters, and Stress Hormones in Methamphetamine-Dependent Patients Undergoing Matrix Treatment Model: A Randomized, Double-Blind Clinical Trial
Azadbakht, A., Salehi, M., Maracy, M. R., & Banafshe, H. R. (2022) · European Addiction Research · doi:10.1159/000525443 · Cited by 10
A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
Celik, M. A., & Fuehrlein, B. (2022) · ImmunoTargets and Therapy · doi:10.2147/itt.s370435 · Cited by 10
“Methamphetamine and its compound amphetamine are in the class of substituted phenethylamines.(76) These strong psychostimulants modulate multiple neurotransmitters, including dopamine, norepinephrine, serotonin, GABA, and histamine, via inhibiting vesicular monoamine transporters and dysregulation of transmitters at n…”
Background
A Method to Quantify Illicit Intake of Drugs from Urine: Methamphetamine
Li, L., Galloway, G. P., Verotta, D., Everhart, E. T., Baggott, M. J., Coyle, J., López, J. C. R., & Mendelson, J. E. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179176 · Cited by 10
“Unfortunately, despite an intense effort over the last 20 years, no medications have been proven effective for the treatment of MA addiction (Karila et al., 2010).”
Background
Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice
Chen, Y., Wu, K., Wu, K.-L., Wu, K.-L., Tsai, H.-M., Chen, M.-L., Chen, Y.-W., Hsieh, W., Lin, C.-M., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/srep46301 · Cited by 10
3-Aryl-3-arylmethoxyazetidines. A new class of high affinity ligands for monoamine transporters
Thaxton-Weissenfluh, A., Izenwasser, S., Wade, D., Stevens, E. D., Mobley, D. L., Jaber, V. R., Lomenzo, S. A., & Trudell, M. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.071 · Cited by 10
Metoprine, a histamine N-methyltransferase inhibitor, attenuates methamphetamine-induced hyperlocomotion via activation of histaminergic neurotransmission in mice
Kitanaka, N., Hall, F. S., Kobori, S., Kushihara, S., Oyama, H., Sasaoka, Y., Takechi, M., Tanaka, K., Tomita, K., Igarashi, K., et al. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173257 · Cited by 9
Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice
Kitanaka, N., Kitanaka, J., Hall, F. S., Kayama, M., Sugimori, H., Uhl, G. R., & Takemura, M. (2015) · Journal of Experimental Neuroscience · doi:10.4137/jen.s27733 · Cited by 9
Reciprocal Substitution Between Methamphetamine and Heroin in Terms of Reinforcement Effects in Rats
Mei, D., Cai, Y., Wang, F.-M., Ma, B., Liu, H., Zhou, W., & Xu, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00750 · Cited by 9
Alleviation of Cocaine Withdrawal and Pertinent Interactions between Salvinorin-Based Antagonists and Kappa Opioid Receptor
Akins, N. S., Mohammed, S., Pandey, P., Kim, S. J., Mahdi, F., Khan, M. I. H., Moss, E. M., Worth, C. J., Keane, M. M., Chittiboyina, A. G., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00806 · Cited by 9
Organic cation transporters in psychiatric and substance use disorders
Honan, L. E., Fraser‐Spears, R., & Daws, L. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108574 · Cited by 9
Neonatal exposure to lipopolysaccharide enhances methamphetamine-induced reinstated behavioral sensitization in adult rats
Tien, L., Cai, Z., Rhodes, P. G., & Fan, L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.038 · Cited by 9
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 9
The effect of an education program based on the family-centered empowerment model on addiction severity among methamphetamine users
Ghasemi, A., Chehregosha, M., Dastoorpoor, M., kolsoumTomaj, O., Farizi, M., Aghababaeian, H., Jamshidi, E., Khanjani, N., & Kouhpayeh, S. A. (2018) · Mental Health & Prevention · doi:10.1016/j.mhp.2018.07.002 · Cited by 8
Applying behavioral activation to sustain and enhance the effects of contingency management for reducing stimulant use among individuals with HIV infection
Mimiaga, M. J., Closson, E. F., Pantalone, D. W., Safren, S. A., & Mitty, J. A. (2018) · Psychology Health & Medicine · doi:10.1080/13548506.2018.1515492 · Cited by 8
“Available pharmacologic and behavioral treatment options for stimulant use disorder are limited (Karila et al., 2011; Karila et al., 2010; Lee & Rawson, 2008).”
Background
In vivo evaluation of effects of histamine H3 receptor antagonists on methamphetamine-induced hyperlocomotion in mice
Kitanaka, J., Kitanaka, N., Hall, F. S., Amatsu, Y., Hashimoto, K., Hisatomi, E., Kitao, E., Mimura, M., Nakamura, M., Ozawa, R., et al. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146873 · Cited by 8
NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats
Kučerová, J., Amchová, P., Siska, F., & Tizabi, Y. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1907714 · Cited by 9
“Despite extensive research, there is still no specific pharmacological intervention to combat METH addiction (Karila et al. 2010; Schmitz et al. 2019).”
Background
Pedunculopontine arousal system physiology—Effects of psychostimulant abuse
Urbano, F. J., Bisagno, V., González, B., Rivero‐Echeto, M. C., Muñiz, J. A., Luster, B. R., D’Onofrio, S., Mahaffey, S., & García‐Rill, E. (2015) · Sleep Science · doi:10.1016/j.slsci.2015.09.004 · Cited by 8
“regulate P/Q-type calcium channels [34,35], which would med-”
Protocol for a systematic review of psychological treatment for methamphetamine use: An analysis of methamphetamine use and mental health symptom outcomes
Stuart, A., Baker, A. L., Bowman, J., McCarter, K., Denham, A. M. J., Lee, N., Colyvas, K., & Dunlop, A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015383 · Cited by 7
“Pharmacotherapies have been used in conjunction with the aim of improving treatment engagement and retention;(21) however, research on the efficacy of pharmacotherapies to date has produced inconsistent results.(22) There is no evidence to suggest that agonist drug treatments can reduce psychological distress associat…”
Method
Amantadine reduces persistent fatigue during post-acute withdrawal phase in methamphetamine abstained individuals: A randomized placebo-controlled trial
Modarresi, A., Eslami, K., Kouti, L., Hassanvand, R., Javadi, M., & Sayyah, M. (2018) · Journal of Substance Use · doi:10.1080/14659891.2018.1459904 · Cited by 7
“In addition, postacute withdrawal symptoms, such as persistent fatigue, can increase the risk of relapse, especially in those who use methamphetamine to increase or sustain work performance (Karila et al., 2010; McGregor et al., 2005).”
Background
Utilizing Soccer for Delivery of HIV and Substance Use Prevention for Young South African Men: 6-Month Outcomes of a Cluster Randomized Controlled Trial
Rabie, S., Tomlinson, M., Almirol, E. A., Stewart, J., Skiti, Z., Weiss, R. E., Vogel, L., & Rotheram‐Borus, M. J. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03819-x · Cited by 7
“Accordingly, due to the limited evidence for psychosocial treatment of methamphetamine use, the treatment focus in recent years has shifted to pharmacotherapies and medication [49, 50].”
Background
Attenuation of Methamphetamine-Induced conditioned place preference in Mice after a Drug-Free period and Facilitation of this effect by exposure to a Running Wheel
Kitanaka, N., Kitanaka, J., Hall, F. S., Uhl, G. R., Watabe, K., Kubo, H., Takahashi, H., & Takemura, M. (2012) · Journal of Experimental Neuroscience · doi:10.4137/jen.s10046 · Cited by 7
“METH CPP did not differ between the housing groups (main group effect F(2,15) = 0.”
BackgroundResultInfluential
Concomitant abuse of methadone and methamphetamine could impair spatial learning and memory in male rats
Nouri, F., Afarinesh, M. R., Sheibani, V., Foroumadi, A., Esmaeili‐Mahani, S., Mahmoudi, M., & Rohani, E. (2019) · Learning and Motivation · doi:10.1016/j.lmot.2019.01.001 · Cited by 7
Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence
Kitanaka, N., Hall, F. S., Uhl, G. R., & Kitanaka, J. (2019) · Current Drug Research Reviews · doi:10.2174/2589977511666190620141824 · Cited by 8
Chronic treatment with curcumin enhances methamphetamine locomotor sensitization and cue-induced reinstatement of methamphetamine self-administration
Zhao, C., Lou, Z., Zimmer, B., Yu, Z., Li, P., Ma, B., Sun, Y., Huang, K., Zhou, W., & Liu, Y. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.06.011 · Cited by 7
“Alteration of 5-HT systems has been suggested to be an effective treatment option for METH addiction (Karila et al., 2010; Takamatsu et al., 2006).”
Therapeutic targeting of neuroinflammation in methamphetamine use disorder
Jeffery, N., Mock, P. Y., Yang, K., Tham, C. L., Israf, D. A., Li, H., Wang, X., & Lam, K. W. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2447226 · Cited by 7
No evidence of subgroups found in amphetamine consumers in Iran
Bananej, A., Völkl-Kernstock, S., Lesch, O., Walter, H., & Skala, K. (2018) · Neuropsychiatrie · doi:10.1007/s40211-018-0259-0 · Cited by 6
“The subgroups investigated here do not correspond to those already described, where consumers are classified into social users and functional users [4, 9, 27], but seem to be associated with underlying psychiatric conditions [13].”
Background
Treatment of Methamphetamine Dependence with Electroconvulsive Therapy (ECT) in Iran: A Critical Note.
Roshanaei-Moghaddam, B., & Pauly, M. C. (2014) · Europe PMC (PubMed Central) · Cited by 6
Efficacy of Psychostimulant Drugs for Amphetamine Abuse or Dependence
Pérez‐Mañá, C., Cervelló, X. C., Torrens, M., Capellà, D., & Farré, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009695 · Cited by 6
How does methamphetamine affect the brain? A systematic review of magnetic resonance imaging studies
Liu, G. X. H., Tayebi, M., Bristow, B., Wang, J., Lin, Y., Newburn, G., Condron, P., McHugh, P., Schierding, W. S., Holdsworth, S. J., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112862 · Cited by 5
The Effectiveness of Mindfulness in the Treatment of Methamphetamine Addiction Symptoms: Does Neuroplasticity Play a Role?
Chmiel, J., Malinowska, A., Rybakowski, F., & Leszek, J. (2024) · Brain Sciences · doi:10.3390/brainsci14040320 · Cited by 10
“Clinical trials with aripiprazole, SSRIs, ondansetron, mirtazapine, and GABA drugs (gabapentin, baclofen, and vigabatrin) have demonstrated no significant effectiveness [48].”
Background
Cabergoline in Treatment of Methamphetamine-Dependent Patients and Its Effect on Serum Level of Glial Cell-Derived Neurotrophic Factor: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Alipour, M., Jafarian, M., Sisakht, R. R., Mokri, A., Gorji, A., Zarrindast, M., Lorestani, F., & Razaghi, E. M. (2021) · European Addiction Research · doi:10.1159/000515398 · Cited by 5
The Neurobiology of Methamphetamine Addiction and the Potential to Reduce Misuse Through Conjugate Vaccines Targeting Toll-Like Receptor 4
Prasad, S., Mathew, P. S., Piper, B. J., Kaur, K., & Tian, M. Y. (2023) · Cureus · doi:10.7759/cureus.40259 · Cited by 5
“With increased withdrawal effects, the brain sends corticotropin-releasing factor, norepinephrine, and dynorphins into the extended amygdala which contributes to the negative emotional states [45].”
Background
Crystal-Meth als Herausforderung für das Suchthilfesystem – Klinische Empfehlungen
Härtel-Petri, R. (2015) · Suchttherapie · doi:10.1055/s-0035-1559657 · Cited by 5
Effects of Methamphetamine Toxicity on the Nervous System
Asar, S. H., Sharifabad, M. H., & Yadegari, M. (2018) · The Neuroscience Journal of Shefaye Khatam · doi:10.29252/shefa.6.3.91 · Cited by 5
Regional Disparities in Prescription Methamphetamine and Amphetamine Distribution Across the United States
Lopera, S. D., O’Kane, V. M., Goldhirsh, J. L., & Piper, B. J. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231177467 · Cited by 5
“exposure is enough to establish dependency (Karila et al., 2010).”
BackgroundInfluential
Electroconvulsive seizures protect against methamphetamine-induced inhibition of neurogenesis in the rat hippocampus
García‐Cabrerizo, R., Bis‐Humbert, C., & García-Fuster, M. J. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.08.008 · Cited by 5
The role of brain creatine in behavioral health conditions
Han, E. S., Yancey, J. R., Yurgelun-Todd, D. A., Kondo, D. G., Boxer, D., & Renshaw, P. F. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1667639 · Cited by 5
“Other medications such as vigabatrin, ondansetron, topiramate, and gabapentin are under investigation, but their ef ﬁ cacy for MUD has not yet been established (83).”
Methamphetamine use among substance use disorder treatment populations
Olatunji, E., Bally, D. J., Oke, O. K., Tumenta, T., Umesi, U. N., Vyas, V., & Nkemjika, S. (2025) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2025.100192 · Cited by 4
Co-treatment with low doses of buspirone prevents rewarding effects of methylphenidate and upregulates expression of 5-HT1A receptor mRNA in the nucleus accumbens
Haleem, D. J., Salman, T., Nawaz, S., & Ikram, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113660 · Cited by 4
Inhalant Self-Administration of Methamphetamine: The Most Similar Model to Human Methamphetamine Addiction
Rafaiee, R., Ahmadiankia, N., Mousavi, S. A., Rezaeian, L., Sarvandani, M. N., Shekari, A., Forouzesh, M., Valipour, R., & Moghaddam, H. K. (2019) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.90561 · Cited by 4
“Currently, there is no efficient or standard treatment for meth addiction (5).”
Background
Sex differences in the multilevel determinants of injection risk behaviours among people who inject drugs in Tijuana, Mexico
Jain, J. P., Strathdee, S. A., West, B. S., González‐Zúñiga, P., Rangel, G., & Pitpitan, E. V. (2020) · Drug and Alcohol Review · doi:10.1111/dar.13134 · Cited by 4
“Future interventions in Tijuana should scale-up access to medication-assisted treatments for opioid use disorder [46], develop pharmacotherapies for stimulant use disorder [47] and consider delivering medication treatments in conjunction with proven behavioural therapies [48].”
Background
Use of gabapentin with or without a prescription in substance use treatment settings: A national analysis of urine drug testing data, 2016–2023
Ellis, M. S., Whitley, P., & Passik, S. D. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113020 · Cited by 3
“If You Plant That Seed, It Will Grow”: A Qualitative Study to Improve Linkage to Care Among Patients With Methamphetamine Use Disorder in Emergency Department Settings
Rinehart, D. J., Duarte, K. G., Gilbert, A., Al‐Tayyib, A., Camfield, K., & Simpson, S. A. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001315 · Cited by 3
“(Meth) Will Hurt You and Hurt Your Teeth”: Teen, Parent, and Dental Practitioner Perspectives on Implementing Crystal Meth Use Prevention Messaging in the Dental Office Setting
Skeer, M. R., Landy, D. M., Ryan, E. C., Lee-Bravatti, M., Boyadjian, T., & Towers, J. (2022) · International Journal of Dentistry · doi:10.1155/2022/6933091 · Cited by 3
“Given the devastating eﬀects of meth use disorders [9], there is a need for innovative meth use prevention strategies targeted toward youth, particularly in rural areas, where meth use poses a signiﬁcant risk for adolescents [10].”
Differences in the prevalence and clinical correlates of depressive symptoms in male patients with methamphetamine and heroin use disorder in a Chinese Han population
Zhu, R., Wang, D., Fan, F., Fu, F., Wei, D., Tang, S., Tian, Y., Chen, J., Li, Y., Zhou, H., et al. (2023) · American Journal on Addictions · doi:10.1111/ajad.13476 · Cited by 3
Pharmacotoxicology of Substances of Abuse
Pacifici, R., Pichini, S., Pellegrini, M., & Berretta, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-24958-7_53 · Cited by 3
Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study
Webber, H. E., Badawi, J. C., Calvillo, D. J., Yoon, J., Weaver, M. F., Lane, S. D., & Schmitz, J. M. (2024) · Journal of Addictive Diseases · doi:10.1080/10550887.2024.2434298 · Cited by 3
Methanol extract from radix of Glycyrrhizae uralensis attenuate methamphetamine-induced hyperlocomotor activity
Zhao, Z., Wang, Y., Lin, F., Fu, H., Zhou, F., Chang, S., Han, N. R., Jung, D. H., Yang, C. H., Kim, S. C., et al. (2014) · Herbal Formula Science · doi:10.14374/hfs.2014.22.1.105 · Cited by 3
“Administration of Meth increases extracellular DA levels [18] in the Nacc by (1) up-regulating tyrosine hydroxylase, the rate-limiting step in DA synthesis, (2) inducing reverse transport of monoamines, (3) blocking the activity of the intracellular vesicular monoamine transporter 2, (4) decreasing the expression of t…”
Background
Money well‐spent: Further evidence of improved outcomes for methamphetamine users following treatment
Manning, V., Best, D. W., Garfield, J. B. B., ALLSOP, S. J., Berends, L., & Lubman, D. I. (2016) · Drug and Alcohol Review · doi:10.1111/dar.12410 · Cited by 3
How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward
Kitanaka, J. (2017) · Journal of Addiction Medicine and Therapeutic Science · doi:10.17352/2455-3484.000021 · Cited by 3
“Unfortunately, various attempts at pharmacotherapy trials have yielded unpromising and inconsistent results with medications developed to date [15-17].”
Result
Abnormal regional brain activity associated with relapse in early abstinent methamphetamine-dependent individuals
Ma, M., Yu, T., Qin, Z., Zhao, P., Zhao, M., Guo, J., Huang, N., Liu, M., Zhang, K., Cai, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11438-4 · Cited by 2
“Current intervention strategies often focus on pharmacological approaches, yet their efficacy remains limited 15–17 .”
Activation of lateral hypothalamic melanin-concentrating hormone neurons mediates sex-specific patterns of methamphetamine self-administration in rats.
Suarez, M., Kuebler, I. R. K., Schneider, H. M., Vollan, J. D., Hubbard, N. A., & Wakabayashi, K. T. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.116002 · Cited by 2
A retrospective chart review of trends and clinical characteristics of patients with amphetamine-type stimulant use disorder in a tertiary care center of Mumbai
Chougule, A., Adarkar, S. A., Kadam, K., & Parkar, S. (2018) · Journal of Medical Society · doi:10.4103/jms.jms_65_17 · Cited by 2
Quantitative Assessment Methods for the Severity of Drug Dependences and Corresponding Rehabilitation Programs
Wang, M., Qian, Y.-X., Ding, Z., Yuan, C., Yang, X., Liu, Y., & Sun, Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105582 · Cited by 2
Berberine hydrochloride improves cognitive deficiency through hippocampal up-regulation of neurotrophins following inhalant self-administration of methamphetamine.
Mohseni, F., Rafaiee, R., Rezaeian, L., Sarvandani, M. N., & Moghaddam, H. K. (2023) · PubMed Central · doi:10.22038/ijbms.2022.65053.14326 · Cited by 3
“However, to date, there is no Food and Drug Administration (FDA)-approved product (22).”
Background
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3
Stimulant substitution in methamphetamine dependence
Dobry, Y., & Sher, L. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412450621 · Cited by 2
“Data on the relapse reduction potential of the medications currently employed in managing this patient population shows modest efficacy at best (Karila et al., 2010).”
Background
Substance-Related and Addictive Disorders
Kosten, T. R., Newton, T. F., Garza, R. D. L., & Haile, C. N. (2014) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585625031.rh23 · Cited by 2
Stimulant Use Disorders and Related Emergencies
Green, A. S. (2019) · Current clinical psychiatry · doi:10.1007/978-3-319-23961-3_3 · Cited by 2
Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report
Johnson, S., & Black, Q. C. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00398-7 · Cited by 4
Methamphetamin
Betzler, F., & Köhler, S. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_67 · Cited by 2
Medication for Cravings in Substance Use Disorders
Patkar, A. A., Lee, J. C., & Burgess, D. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00056-7 · Cited by 2
THE DEVELOPMENT OF THE MARKET ECONOMY IN COLONIAL MASSACHUSETTS
Weiss, R. S. (1981) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · Cited by 2
Regional disparities in prescription methamphetamine and amphetamine distribution across the United States in 2019Preprint
Lopera, S. D., O’Kane, V. M., Goldhirsh, J. L., & Piper, B. J. (2022) · medRxiv · doi:10.1101/2022.05.23.22275471 · Cited by 2
“Unlike other stimulant drugs, drug-seeking behaviors for methamphetamine persist even after tolerance has been reached [6].”
BackgroundInfluential
Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders
Nilson, A. N., Felsing, D. E., & Allen, J. (2022) · Wiley eBooks · doi:10.1002/9781119564782.ch19 · Cited by 2
Modafinil for the Treatment of Methamphetamine Dependence
Lashkaripour, K., Adibi, A., Mashhadi, F. F., & Dashipour, A. (2016) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.37660 · Cited by 1
Are Histamine H3 Antagonists the Definitive Treatment for Acute Methamphetamine Intoxication?
Kitanaka, N., Kitanaka, J., Hall, F. S., Tanaka, K., Tomita, K., Igarashi, K., Nishiyama, N., Sato, T., & Uhl, G. R. (2022) · Current Drug Research Reviews · doi:10.2174/2589977514666220414122847 · Cited by 1
A qualitative study of interest in and preferences for potential medications to treat methamphetamine use disorder
Wagner, K. D., Marks, C., Fiuty, P., Harding, R. W., & Page, K. A. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00401-1 · Cited by 1
“There are currently no FDA-approved pharmacothera-pies to treat (MUD; [6, 7]), though preliminary studies on some medications (i.e., mirtazapine, modafinil, bupro-pion, naltrexone, and agonist replacement medications) have demonstrated promising (but small) effects [8–11].”
Background
Profiling gene alterations in striatonigral neurons associated with incubation of methamphetamine craving by cholera toxin subunit B-based fluorescence-activated cell sorting
Altshuler, R. D., Burke, M. A. M., Garcia, K. T., Class, K., Cimbro, R., & Li, X. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1542508 · Cited by 1
Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in mice
Matsuda, K., Kitanaka, N., Hall, F. S., Hamana, T., Nakai, M., Yuze, S., Tomita, K., Igarashi, K., Sato, T., Uhl, G. R., et al. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000853 · Cited by 1
Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Methamphetamine‐Associated Heart Failure in the United States
Zhu, A. Y., Chen, A. Y., Deluna, A., Bounthavong, M., Zhao, S. X., & Crawford, M. H. (2026) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.125.045334 · Cited by 1
“49,50 Additionally, multidisciplinary counseling coupled with contingency management programs have demonstrated some success.”
Anhedonia in Mouse Models of Methamphetamine-Induced Drug Seeking Behavior
Kitanaka, J., Kitanaka, N., Hall, F. S., Uhl, G. R., & Takemura, M. (2014) · Springer eBooks · doi:10.1007/978-94-017-8591-4_12 · Cited by 1
The effects of naltrexone on neural responses to methamphetamine cues
Courtney, K. E., Ghahremani, D. G., & Ray, L. A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.141 · Cited by 1
“A focused review on pharmacological treatments for methamphetamine/amphetamine dependence identified only three double-blind placebo-controlled trials that have shown positive 26 results for reducing use of the substance (Karila et al., 2010).”
Background
Vaccines for Methamphetamine Use Disorder
Kosten, T. R., & Kosten, T. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_5 · Cited by 1
Methamphetaminabhängigkeit in Deutschland
Franke, A. G., Soyka, M., & Neumann, S. (2016) · Nervenheilkunde · doi:10.1055/s-0037-1616445 · Cited by 1
Evaluating Amphetamine and Methamphetamine Abuse Frequency in Hospitalized Patients of the Psychiatric Ward of Farshchian Hospital in Hamadan City
Jahangard, L., Haghighi, M., Akhzar, K. M., Seifrabei, M. A., Ahmadpanah, M., Mousavi, L., & Keshavarzi, A. (2017) · مجله پزشکی بالینی ابن سینا · doi:10.21859/hums-240111 · Cited by 1
Substance-Related and Addictive Disorders
Grimaldi, J. A., Bodnar, J., Lavin, D., McLaughlin, M. L., Rasimas, J. J., & Ashley, K. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-80665-1_11 · Cited by 1
Neonatal brain inflammation enhances methamphetamine-induced reinstated behavioral sensitization in adult rats analyzed with explainable machine learning
Wang, K.-C., Ojeda, N. B., Wang, H., Chiang, H., Tucci, M. A., Lee, J. W., Wei, H.-C., Kaizaki‐Mitsumoto, A., Tanaka, S., Dankhara, N., et al. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105743 · Cited by 1
Immunomodulatory effects of detoxification agents on dendritic cell populations in methamphetamine addiction
Mosayebi, G., Moazzeni, S. M., Farahani, H., Solhi, H., Rafiei, M., & Ghazavi, A. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00943-x · Cited by 1
“This combination aims to address both psychological and physical aspects of withdrawal, enhancing overall treatment efficacy [19–21].”
AAV‐Mediated Expression of Methamphetamine Monoclonal Antibody Attenuates Methamphetamine Behaviour Sensitization in Mice
Chen, Y., Hung, T., Wang, Y.-S., Bae, E., Wu, K., Wang, Y., & Yu, S. (2025) · Addiction Biology · doi:10.1111/adb.70073 · Cited by 1

Authors: Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L.
Affiliations: Inserm (FR)
Hadassah Medical Center (IL)
San Francisco VA Medical Center (US)
Corresponding author: Karila, Laurent
ORCID: Karila, Laurent
Weinstein, Aviv
Aubin, Henri‐Jean
Benyamina, Amine
Reynaud, Michel
Batki, Steven L.
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 2010-05-10
Volume: 69
Issue: 6
Pages: 578-592
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1111/j.1365-2125.2010.03639.x
PMC: PMC2883750
OpenAlex: W1747110054
Cited by: 242
References: 135
Citations by year: 2026: 8 · 2025: 11 · 2024: 9 · 2023: 12 · 2022: 16 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 20 · 2017: 15 · 2016: 18 · 2015: 12 · 2014: 16 · 2013: 18 · 2012: 29
FWCI: 2.46
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Drug Abuse (U10DA015815, R01DA016764, UG1DA015815)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords: methamphetamine dependence, pharmacotherapy, partial dopamine agonist, aripiprazole, GABAergic agents, gabapentin, serotonergic agents, modafinil, bupropion, naltrexone, d-amphetamine, methylphenidate, drug addiction
MeSH terms: Animals, Calcium Channel Blockers, Humans, Immunotherapy, Methamphetamine, Narcotic Antagonists, Antipsychotic Agents, Neurotransmitter Agents, Amphetamine-Related Disorders, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacological approaches to methamphetamine dependence: a focused review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks